Bulletin Du Cancer最新文献

{"title":"Toripalimab en association avec le cisplatine et le paclitaxel, en première ligne des carcinomes épidermoïdes de l’œsophage avancés","authors":"Coralie Prevost , Matthieu Delaye","doi":"10.1016/j.bulcan.2025.02.010","DOIUrl":"10.1016/j.bulcan.2025.02.010","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 558-560"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visions croisées de la cancérologie de demain","authors":"Jacques-Olivier Bay , Philippe Pourquier , Stéphane Vignot , Nathalie Mazure","doi":"10.1016/j.bulcan.2025.05.002","DOIUrl":"10.1016/j.bulcan.2025.05.002","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 553-554"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zolbétuximab en association à la chimiothérapie dans les adénocarcinomes gastriques ou de la jonction œsogastrique localement avancés non résécables ou métastatiques, HER2 négatifs et CLDN 18.2 positifs","authors":"Léa Jehanno, Juliette Logeart","doi":"10.1016/j.bulcan.2025.02.011","DOIUrl":"10.1016/j.bulcan.2025.02.011","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 561-562"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0007-4551(25)00209-7","DOIUrl":"10.1016/S0007-4551(25)00209-7","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Page iii"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment guidelines/propositions, on behalf of French multidisciplinary working group on bone primary tumours GroupOs","authors":"Valentine Martin ,&nbsp;Stéphanie Bolle ,&nbsp;Line Claude ,&nbsp;Sylvie Helfre ,&nbsp;Nathalie Gaspar","doi":"10.1016/j.bulcan.2025.01.012","DOIUrl":"10.1016/j.bulcan.2025.01.012","url":null,"abstract":"<div><div>Osteosarcomas are radioresistant tumors whose first-line treatment is based on chemotherapy and surgery. To better define the role of radiotherapy, we carried out a review of the literature from the 2000s concerning children and adults. Radiotherapy can be offered post-operatively in cases of R1 resection, at a minimum dose of 60<!--> <!-->Gy. It is also used exclusively for unresectable tumors, with higher doses. The use of hadrons seems promising. Radiotherapy under stereotactic conditions can be considered for lung and bone metastases. Finally, adaptation of systemic treatments is necessary during irradiation.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 592-600"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment optimiser la prise en charge des patients de cancers urothéliaux localement avancés et ou/métastatique ?","authors":"Nadine Houédé ,&nbsp;Philippe Barthelemy ,&nbsp;Aurélien Gobert ,&nbsp;Benjamin Pradere ,&nbsp;Géraldine Pignot","doi":"10.1016/j.bulcan.2025.02.020","DOIUrl":"10.1016/j.bulcan.2025.02.020","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 681-683"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ostéosarcome et sarcome d’Ewing récurrents ou réfractaires – Directives françaises des groupes FSG/NETSARC et GroupOs","authors":"Mehdi Brahmi ,&nbsp;Maud Toulmonde ,&nbsp;Sarah Winter ,&nbsp;Sixtine De Percin ,&nbsp;Thibaud Valentin ,&nbsp;Nadège Corradini ,&nbsp;Justine Gantzer ,&nbsp;Perrine Marec-Berard ,&nbsp;François Gouin ,&nbsp;Line Claude ,&nbsp;Anne Ducassou ,&nbsp;Nathalie Gaspar ,&nbsp;Camille Tlemsani ,&nbsp;Pablo Berlanga ,&nbsp;GroupOs (Groupe de travail multidisciplinaire des tumeurs osseuses français)","doi":"10.1016/j.bulcan.2024.03.010","DOIUrl":"10.1016/j.bulcan.2024.03.010","url":null,"abstract":"<div><div>Les ostéosarcomes et les sarcomes d’Ewing sont les deux tumeurs osseuses malignes les plus fréquentes chez les enfants, adolescents et jeunes adultes. En cas de récidive de la maladie, le taux de survie globale est faible, avec uniquement environ un tiers des patients ayant une survie à long terme sans maladie. En cas de maladie récurrente ou réfractaire la stratégie thérapeutique doit être discutée lors de réunions multidisciplinaires avec expertise dans la prise en charge des sarcomes osseux. La prise en charge des patients avec un ostéosarcome récurrent ou réfractaire dépend de l’intervalle sans maladie ainsi que du nombre et des sites des métastases et est principalement chirurgicale chez les patients présentant des métastases pulmonaires isolées ou une rechute locale. D’autre part, la chimiothérapie conventionnelle reste la norme pour les patients avec un sarcome d’Ewing récurrent ou réfractaire et comprend l’ifosfamide à haute dose, le cyclophosphamide avec le topotécan et l’irinotécan avec le témozolomide.</div></div><div><div>Osteosarcoma (OS) and Ewing Sarcoma (ES) are the two most frequent malignant bone tumors in children, adolescents and young adults. In case of disease recurrence, both are characterized by an aggressive behaviour and a relatively poor overall survival rate, with approximately a third of patients having a long-term disease-free survival. In case of recurrent or refractory (R/R) disease, the therapeutic strategy should be discussed in multidisciplinary staff meetings with expertise in bone sarcoma management. The standard management of R/R OS depends on the disease-free interval and the number and sites of metastases and is primarily surgical in patients with isolated lung metastases or local relapse. On the other hand, conventional chemotherapy remains the standard for R/R ES and include high-dose ifosfamide, cyclophosphamide with topotecan and irinotecan with temozolomide.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 601-610"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommandations françaises de prise en charge des tumeurs d’Ewing métastatiques extra-pulmonaires (GroupOs)","authors":"Sarah Winter ,&nbsp;Thibaud Valentin ,&nbsp;Anne Ducassou ,&nbsp;Sylvie Helfre ,&nbsp;Pablo Berlanga ,&nbsp;Lauriane Lemelle ,&nbsp;Aude Marie-Cardine ,&nbsp;Pascaline Boudou Rouquette ,&nbsp;Valérie Laurence","doi":"10.1016/j.bulcan.2024.01.014","DOIUrl":"10.1016/j.bulcan.2024.01.014","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Le pronostic des patients atteints d’un sarcome d’Ewing avec métastases extra-pulmonaires est sombre. Un protocole français récent, CombinaiR3, a eu pour but d’évaluer l’efficacité chez ces patients d’une chimiothérapie d’induction, suivie par une chimiothérapie haute dose et un traitement d’entretien métronomique. Dans l’attente des résultats de ce protocole, nous proposons un consensus national français sur la prise en charge de ces patients. Le schéma global proposé reprend dans les grandes lignes celui de CombinaiR3. Concernant la prise en charge initiale, une chimiothérapie d’induction alternant les cures de vincristine/doxorubicine/cyclphosphamide et d’ifosfamide/étoposide, pour un total de neuf cures est recommandée. En cas de réponse radiologique et/ou métabolique insuffisante, un &lt;em&gt;switch&lt;/em&gt; pour un autre schéma de chimiothérapie ou l’inclusion dans un essai thérapeutique devront être discutés. Le traitement local est essentiel dans la prise en charge des patients avec un sarcome d’Ewing. Il consiste en une chirurgie et/ou radiothérapie. Il devra être discuté si possible en amont dès le diagnostic et réalisé par des experts travaillant au sein du réseau sarcomes. Une chimiothérapie haute dose par busulfan et melphalan avec support de cellules souches hématopoïétiques pourra ensuite être administrée si elle est compatible avec le traitement local notamment radiothérapie. Ce programme thérapeutique se terminera par un traitement d’entretien métronomique pendant deux ans.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination. Main recommendations include induction chemotherapy with nine cycles of vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide. In case of insufficient response, other chemotherapy combination or inclusion in a clinical trial should be considered. Induction chemotherapy should be followed by local treatment, consisting of surgery and/or radiotherapy. Optimal local treatment is a milestone in the management of patients with Ewing sarcoma and should be discussed with experts and surgeons/radiotherapists working in the sarcoma network. High-dose chemotherapy (HDC) containing busulfan and melphalan followed by autologous stem-cell transplantation is still unclear, with contradictory results. HDC will then be discussed in national tumor board and administered to patients when compatible with local treatment. Given the high relapse rate observed among these metastatic patients, maintenance chemotherapy (so called metronomic regimen) will then be given for two year","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 619-625"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfortumab-védotine en association avec le pembrolizumab en première ligne dans le carcinome urothélial avancé/métastatique","authors":"Elise Vandra,&nbsp;Mathieu Jamelot","doi":"10.1016/j.bulcan.2025.03.003","DOIUrl":"10.1016/j.bulcan.2025.03.003","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 564-566"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ours redaction EDB","authors":"","doi":"10.1016/S0007-4551(25)00207-3","DOIUrl":"10.1016/S0007-4551(25)00207-3","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Page i"},"PeriodicalIF":1.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}